{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:26:37Z","timestamp":1783365997538,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41375-025-02534-5","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:17:50Z","timestamp":1740392270000},"page":"1001-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-1091","authenticated-orcid":false,"given":"Amber R.","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman S.","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-3879","authenticated-orcid":false,"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mendizabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita Y.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Somlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"2534_CR1","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"2534_CR2","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1515\/cclm-2019-0368","volume":"58","author":"PV Bottini","year":"2020","unstructured":"Bottini PV, Garlipp CR, Lima PRM, Brito IT, Carvalho LMG. Are patients adequately informed about procedures for 24-h urine collection? Clin Chem Lab Med. 2020;58:e32\u2013e35. https:\/\/doi.org\/10.1515\/cclm-2019-0368","journal-title":"Clin Chem Lab Med"},{"key":"2534_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1080\/10428194.2023.2201365","volume":"64","author":"KH Natsuhara","year":"2023","unstructured":"Natsuhara KH, Huang CY, Knoche J, Arora S, Chung A, Martin T, et al. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leuk Lymphoma. 2023;64:1186\u201393. https:\/\/doi.org\/10.1080\/10428194.2023.2201365","journal-title":"Leuk Lymphoma"},{"key":"2534_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.4065\/81.12.1575","volume":"81","author":"JA Katzmann","year":"2006","unstructured":"Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81:1575\u20138. https:\/\/doi.org\/10.4065\/81.12.1575","journal-title":"Mayo Clin Proc"},{"key":"2534_CR5","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1182\/blood-2018-99-113508","volume":"132","author":"RB Foster","year":"2018","unstructured":"Foster RB, Lipitz NG, Torres AZ, Carson KR. The real-world frequency of 24-hour urine protein electrophoresis (UPEP), serum free light chain (SFLC), and serum protein electrophoresis (SPEP) testing in patients with multiple myeloma (MM). Blood. 2018;132:3536\u20133536. https:\/\/doi.org\/10.1182\/blood-2018-99-113508","journal-title":"Blood"},{"key":"2534_CR6","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2016-07-726778","volume":"128","author":"T Dejoie","year":"2016","unstructured":"Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood. 2016;128:2941\u20138. https:\/\/doi.org\/10.1182\/blood-2016-07-726778","journal-title":"Blood"},{"key":"2534_CR7","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood.2019000671","volume":"133","author":"JJ Lahuerta","year":"2019","unstructured":"Lahuerta JJ, Jim\u00e9nez-Ubieto A, Paiva B, Mart\u00ednez-Lopez J, Gonz\u00e1lez-Medina J, L\u00f3pez-Anglada L, et al. Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood. 2019;133:2664\u20138. https:\/\/doi.org\/10.1182\/blood.2019000671","journal-title":"Blood"},{"key":"2534_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589\u201397. https:\/\/doi.org\/10.1200\/JCO.18.00685","journal-title":"J Clin Oncol"},{"key":"2534_CR9","doi-asserted-by":"publisher","first-page":"e19517","DOI":"10.1200\/jco.2013.31.15_suppl.e19517","volume":"31","author":"NS Callander","year":"2013","unstructured":"Callander NS, Jacobus SJ, Weiss M, Kumar S, Fonseca R, Siegel DSD, et al. Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple myeloma (MM). J Clin Oncol. 2013;31:e19517\u2013e19517. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.e19517","journal-title":"J Clin Oncol"},{"key":"2534_CR10","doi-asserted-by":"publisher","first-page":"ofac492.838","DOI":"10.1093\/ofid\/ofac492.838","volume":"9","author":"L Farshidpour","year":"2022","unstructured":"Farshidpour L, Wilson TE, Hauser N, Desai A. 997. Burden of inappropriate urine culture collection and processing on the environment. Open Forum Infect Dis. 2022;9:ofac492.838. https:\/\/doi.org\/10.1093\/ofid\/ofac492.838","journal-title":"Open Forum Infect Dis"},{"key":"2534_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41375-018-0339-y","volume":"33","author":"T Dejoie","year":"2019","unstructured":"Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia. 2019;33:313\u20138. https:\/\/doi.org\/10.1038\/s41375-018-0339-y","journal-title":"Leukemia"},{"key":"2534_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2024-208790","volume":"144","author":"E Askari","year":"2024","unstructured":"Askari E, Dispenzieri A, Baudi FK, Hayman SR, Gertz MA, Kapoor P, et al. Impact of serial serum free light chain measurements on response and progression assessments in multiple myeloma patients with measurable disease. Blood. 2024;144:1955\u20131955. https:\/\/doi.org\/10.1182\/blood-2024-208790","journal-title":"Blood"},{"key":"2534_CR13","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"key":"2534_CR14","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.ekir.2024.03.033","volume":"9","author":"N Leung","year":"2024","unstructured":"Leung N, Comenzo R, Gillmore J, Havasi A, Kastritis E, Guthrie S, et al. Renal Response criteria for clinical trials in amyloid light chain amyloidosis. Kidney Int Rep. 2024;9:1986\u201394. https:\/\/doi.org\/10.1016\/j.ekir.2024.03.033","journal-title":"Kidney Int Rep"},{"key":"2534_CR15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00277-020-03983-x","volume":"99","author":"E Riva","year":"2020","unstructured":"Riva E, Schutz N, Pena C, Ruiz-Arguelles G, Hopkins CR, Bove V, et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. Ann Hematol. 2020;99:1025\u201330. https:\/\/doi.org\/10.1007\/s00277-020-03983-x","journal-title":"Ann Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02534-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:45:48Z","timestamp":1744033548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02534-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2534"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02534-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB reports: consulting, Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Gilead, Janssen, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. CLF reports: honoraria\/consulting for BMS, Seattle Genetics, Celgene, Abbvie, Sanofi, Incyte, Amgen, and ONK therapeutics, Janssen; research funding from BMS, Janssen and Roche\/Genentech. AJC reports research funding: Janssen, BMS, Juno\/Celgene, Sanofi, Regeneron, IGM biosciences, Nektar, Harpoon, Adaptive Biotechnologies, Caelum, Abbvie; advisory\/consulting: Sebia, Janssen, BMS, Sanofi, HopeAI, Adaptive Biotechnologies, Abbvie. NS reports: research funding from Bristol Myers Squibb\/Celgene, Janssen, bluebird bio, Sutro Biopharma, TeneoBio, Poseida, Nektar, and Precision Biosciences; consultant for GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm Therapeutics, Oncopeptides, and CSL Behring; current employee and equity holder of AstraZeneca. HJL reports: consulting, Abbvie, Immix Biopharma, Legend Biotech, Alexion, Prothena; funding: Janssen, Alexion, Protego, Prothena. SKK reports: funding: Abbvie, Celgene, Janssen, Takeda, Adaptive, Kite, AstraZeneca, Merck, Novartis, Roche, Sanofi. D.T.V. reports: consulting, Celgene, Karyopharm Therapeutics, Janssen, Takeda, GlaxoSmithKline, CSL Behring, Oncopeptides, Genentech, Sanofi; research funding, Active Biotech, Takeda. YAE reports: research funding, Takeda, Oncopeptides, Alnylam, Sanofi, GlaxoSmithKline, ORCA Therapeutics, BMS; consulting: Oncopeptides, Sanofi, Janssen Oncology, Pfizer, speaker\u2019s bureau: Takeda, Janssen, Akcea Therapeutics. PLM reports: consulting: Beigene, BMS\/Celgene\/Juno, Fate Therapeutics, Glaxo Smith Klein, JnJ (Janssen), Karyopharm, Meda Consulting. D.H.V. reports: speaker\u2019s bureau: BMS, Amgen, Takeda, Janssen, Sanofi, Karyopharm, Sanofi. AYK reports: consulting: AbbVie, Bristol Myers Squibb, GSK, JnJ, Pfizer, Regeneron, Sanofi; research funding: JnJ, Roche; speaker\u2019s bureau: BMS, Takeda; stock options: BMS. EAS reports: consulting: Celgene, Takeda, Novartis, Teva, Janssen, Amgen, Sanofi. MCP reports: consulting: BMS; research: Novartis, Janssen, Kite. The remaining authors have no conflicts to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods and study procedures. were performed in accordance with relevant guidelines and regulations. Every participating center in the BMT CTN 0702 trial obtained Institutional Review Board approval for the original study from which data were obtained for this post hoc analysis. Similarly, all study participants provided informed consent for participation in the BMT CTN 0702 trial. No identifiable information was obtained as part of this post hoc analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}